Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
about
A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in SpainBalloon kyphoplasty compared to vertebroplasty and nonsurgical management in patients hospitalised with acute osteoporotic vertebral compression fracture: a UK cost-effectiveness analysis.Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis.Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in SpainBazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis.A systematic review of models used in cost-effectiveness analyses of preventing osteoporotic fractures.A systematic review of cost-effectiveness analyses of drugs for postmenopausal osteoporosis.Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria.Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.Expected lifetime numbers, risks, and burden of osteoporotic fractures for 50-year old Chinese women: a discrete event simulation incorporating FRAX.Cost-effectiveness of bazedoxifene compared with raloxifene in the treatment of postmenopausal osteoporotic women.Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study.
P2860
Q30248756-8B6ADF71-DDD4-4677-907E-0CDE68161E68Q35087883-049B2844-761A-44F3-9B91-82F4975DA41FQ36952494-F5233469-77A7-4273-8F3E-FBC3BF7E2C5EQ36997684-40DFF703-A82F-4B8E-872E-20434FBA0629Q37006842-20BFCC49-B0D6-44DC-B844-36816CF270B7Q37950520-AE08805C-6AB6-4408-AC0A-DF96B70F9C71Q38155095-38EC3359-A138-40BA-A0E3-82C0C5ACE44EQ38265934-97819B44-6E7B-462B-848D-562160EEA330Q39578150-170F263E-3E61-4503-958E-B6B094A16F28Q39888072-33284529-CAFE-457A-96E9-98D7B21648E6Q40506138-B5E39B14-1F32-44F5-BC13-D41598318E52Q43725897-5E81F871-1571-439C-9B3B-1F024124B486Q46795033-F3D88724-E5FB-419E-829F-F100FBA123DDQ48154405-C47F3353-DF75-4713-807F-A08FE98A2A74Q51748877-16EAF877-51BA-40EE-81A3-63DD17D8D2D6
P2860
Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@en
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@nl
type
label
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@en
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@nl
prefLabel
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@en
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@nl
P2093
P2860
P1476
Cost-effectiveness of bazedoxi ...... thm in a European perspective.
@en
P2093
E McCloskey
F Borgström
H Johansson
P2860
P2888
P304
P356
10.1007/S00198-010-1291-5
P407
P577
2010-06-08T00:00:00Z